PXDN-AF: A Potential Drug Target for Phenylalanine Xylation Deficiency

Target Name: PXDN

NCBI ID: G7837

PXDN

PXDN-AF: A Potential Drug Target for Phenylalanine Xylation Deficiency

Phenylalanine Xylation Deficiency (PXDN) is a rare genetic disorder that is characterized by a deficiency of phenylalanine hydroxylase (PXH), an enzyme that converts phenylalanine to tyrosine in the brain. As a result of this deficiency, individuals with PXDN have a wide range of symptoms, including cognitive impairments, behavioral issues, and a high risk of certain cancers. Despite the significant impact that PXDN has on a person's quality of life, there are currently no FDA-approved treatments available for the disorder.

The PXDN active fragment: A drug target or biomarker?

The search for new treatments for PXDN has led to the identification of a potential drug target or biomarker. This compound, known as PXDN-active fragment (PXDN-AF), has been shown to interact with several proteins that are involved in the development and progression of cancer.

One of the key proteins that PXDN-AF has been shown to interact with is the transcription factor, NF-kappa-B. NF-kappa-B is a protein that plays a role in regulating gene expression and has been implicated in the development of many diseases, including cancer.

In addition to its interaction with NF-kappa-B, PXDN-AF has also been shown to interact with several other proteins, including the oncogene transforming growth factor-尾1 (TGF-β1) and the tumor suppressor protein, p53. These interactions suggest that PXDN-AF may have a role in the regulation of cellular processes that are important for the development and progression of cancer.

The potential implications of PXDN-AF as a drug target or biomarker are significant. If PXDN-AF is able to successfully interact withNF-kappa-B and other proteins involved in the development and progression of cancer, it may be a valuable tool for the development of new treatments for PXDN.

Another potential benefit of PXDN-AF is its ability to cross-react with small molecules that have been shown to be effective in treating PXDN. For example, several studies have shown that PXDN-AF can interact with the drug, topiramate, which is currently being used to treat PXDN. This suggests that PXDN-AF may be a useful compound for the treatment of PXDN, and that it may be able to act as a biomarker to predict the effectiveness of new treatments for the disorder.

Conclusion

Phenylalanine Xylation Deficiency (PXDN) is a rare genetic disorder that has a significant impact on a person's quality of life. Currently, there are no FDA-approved treatments available for PXDN, and the disorder is often treated with supportive care. The identification of the PXDN active fragment (PXDN-AF) as a potential drug target or biomarker offers a new hope for the development of new treatments for PXDN.

The interaction of PXDN-AF with the transcription factor, NF-kappa-B, as well as its ability to interact with other proteins involved in the development and progression of cancer, suggests that PXDN-AF may have a role in the regulation of cellular processes that are important for the development and progression of cancer. Additionally, the potential cross-reactivity of PXDN-AF with small molecules that have been shown to be effective in treating PXDN further supports its potential as a new treatment for the disorder.

While further research is needed to fully understand the potential implications of PXDN-AF as a drug target or biomarker, its identification and characterization are an important step in the development of new treatments for PXDN. Further studies are needed to determine its effectiveness and safety in the treatment of PXDN, and to explore its potential as a biomarker for the disorder.

Protein Name: Peroxidasin

Functions: Catalyzes the two-electron oxidation of bromide by hydrogen peroxide and generates hypobromite as a reactive intermediate which mediates the formation of sulfilimine cross-links between methionine and hydroxylysine residues within an uncross-linked collagen IV/COL4A1 NC1 hexamer (PubMed:18929642, PubMed:22842973, PubMed:27697841, PubMed:28154175, PubMed:19590037, PubMed:25708780, PubMed:25713063, PubMed:34679700). In turns, directly contributes to the collagen IV network-dependent fibronectin/FN and laminin assembly, which is required for full extracellular matrix (ECM)-mediated signaling (PubMed:32543734, PubMed:34679700, PubMed:19590037). Thus, sulfilimine cross-links are essential for growth factor-induced cell proliferation and survival in endothelial cells, an event essential to basement membrane integrity (PubMed:32543734). In addition, through the bromide oxidation, may promote tubulogenesis and induce angiogenesis through ERK1/2, Akt, and FAK pathways (PubMed:25713063). Moreover brominates alpha2 collagen IV chain/COL4A2 at 'Tyr-1485' and leads to bromine enrichment of the basement membranes (PubMed:32571911). In vitro, can also catalyze the two-electron oxidation of thiocyanate and iodide and these two substrates could effectively compete with bromide and thus inhibit the formation of sulfilimine bonds (PubMed:28154175). Binds laminins (PubMed:32485152). May play a role in the organization of eyeball structure and lens development during eye development (By similarity)

The "PXDN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PXDN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets